Bristol-Myers Squibb Company (NYSE:BMY) was upgraded by stock analysts at SunTrust Banks, Inc. from a “hold” rating to a “buy” rating in a report issued on Monday, The Fly reports. SunTrust Banks also issued estimates for Bristol-Myers Squibb’s FY2017 earnings at $3.03 EPS, FY2018 earnings at $3.19 EPS, FY2019 earnings at $3.64 EPS, FY2020 earnings at $4.15 EPS and FY2021 earnings at $4.40 EPS.

BMY has been the subject of a number of other research reports. Vetr downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price objective for the company. in a research report on Tuesday, August 22nd. Citigroup Inc. set a $72.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a report on Wednesday, October 25th. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the company a “sell” rating in a report on Thursday. Deutsche Bank AG set a $55.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, July 17th. Finally, Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Wednesday, August 16th. One analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $64.73.

Bristol-Myers Squibb (NYSE:BMY) opened at 59.94 on Monday. The firm has a market capitalization of $98.30 billion, a PE ratio of 21.89 and a beta of 1.19. The company’s 50-day moving average price is $63.55 and its 200 day moving average price is $57.61. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same quarter last year, the company posted $0.77 EPS. Bristol-Myers Squibb’s revenue was up 6.7% on a year-over-year basis. On average, analysts forecast that Bristol-Myers Squibb will post $3.00 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/10/30/bristol-myers-squibb-company-bmy-lifted-to-buy-at-suntrust-banks-inc.html.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore R. Samuels II bought 6,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

A number of institutional investors have recently bought and sold shares of BMY. First Trust Advisors LP grew its position in shares of Bristol-Myers Squibb by 10.7% in the second quarter. First Trust Advisors LP now owns 433,050 shares of the biopharmaceutical company’s stock valued at $24,130,000 after purchasing an additional 41,892 shares during the last quarter. Toronto Dominion Bank grew its position in shares of Bristol-Myers Squibb by 54.0% in the first quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock valued at $25,264,000 after purchasing an additional 162,884 shares during the last quarter. Mutual of America Capital Management LLC grew its position in shares of Bristol-Myers Squibb by 1.9% in the first quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock valued at $10,932,000 after purchasing an additional 3,833 shares during the last quarter. Quantitative Investment Management LLC acquired a new stake in shares of Bristol-Myers Squibb in the first quarter valued at about $6,150,000. Finally, Meridian Management Co. grew its position in shares of Bristol-Myers Squibb by 1.5% in the first quarter. Meridian Management Co. now owns 51,770 shares of the biopharmaceutical company’s stock valued at $2,815,000 after purchasing an additional 770 shares during the last quarter. 68.93% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

The Fly

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.